• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Bioresearch Monitoring Mid-Cycle Review Memo, May 16, 2012 - Octaplas

 

MEMORANDUM         DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
Center for Biologics Evaluation and Research
_____________________________________________________________________
 
DATE                          May 16, 2012
           
FROM                         Christine Drabick, Bioresearch Monitoring Branch, HFM-664
                                    Division of Inspections and Surveillance
Office of Compliance and Biologics Quality
 
THROUGH                 Patricia Holobaugh, Bioresearch Monitoring Branch Chief,
HFM-664
 
TO                               Nancy Kirshbaum, HFM-343, Chair
                                    Pratibha Rana, HFM-380, RPM
                                                                       
SUBJECT                   Bioresearch Monitoring Mid-Cycle Review Memo
SPONSOR: Octapharma AG
PRODUCT: Octaplas LG™ (Human Coagulation Active Plasma for Infusion, Solvent/Detergent Treated)
BLA: STN 125416/0
 
Mid-Cycle Summary:
 
Bioresearch Monitoring inspection assignments were issued for two clinical investigators and two study protocols. The pivotal study, LAS-203, was conducted at a single site in Vienna, Austria. 
 
LAS-201: A Sequential Cohort Study to Compare Tolerability and Efficacy in Patients
      Receiving octaplas or octaplas LG
 
LAS-203: A Comparative, Open-Label, Randomized, Cross-over Phase I Trial in Healthy Volunteers to Investigate the Relative Efficacy, Safety and Tolerability of Octaplas LG™ vs. Octaplas® SD
  
 

Protocol
Study Site
Location
Form FDA 483 Issued
Inspection Final Classification
IND#
LAS-201
Institute of Transfusion Medicine
Nordhausen, Germany
 
No
EIR Pending
None
LAS-203
Medical University of Vienna
Vienna, Austria
Yes
EIR Pending
13956

 
 
The Bioresearch Monitoring inspections at both sites are complete. The Establishment Inspections Reports (EIRs) for both inspections are pending.
 
STUDY PROTOCOL 201
 
Study Protocol 201 was a non-interventional, sequential cohort, observational, open, prospective, multi-center study. Treatment was administered according to normal clinical practice, rather than protocol-specified treatment parameters. This study was not conducted under an IND.
 
The inspection of this observational study was limited due to European data protection regulations (European Parliament and Council Directive 95/46/EC), which state “neither the sponsor, nor authorised representatives from the sponsor or representatives from regulatory authorities are authorised to access and review confidential patient information. For observational studies we do not have an agreement with the patients authorising the entities listed above to access their medical data”.  Informed consent was not required for this observational study and as a result, source documents were not permitted to be reviewed.  Information submitted in the BLA was compared to Case Report Forms (CRFs) and other records available for inspection.
 
During the inspection the FDA investigator was informed that the investigational product was administered by physicians who were not participating in the study and subjects were not enrolled in the study prior to treatment. The study physicians reviewed the records provided by the treating physicians and retrospectively selected subjects to enroll in the study. 
 
The Establishment Inspection Report is pending for this inspection. Based on the information received from the FDA investigator, the source documents for the data submitted in the BLA for study 201 were not available for review, consequently the data submitted in the BLA could not be verified.
 
STUDY PROTOCOL LAS 203
 
Study Protocol LAS 203 was conducted at a single site in Vienna, Austria. A four-item Form FDA 483 was issued to the investigator. The Form FDA 483 observations included: failure to maintain adequate and accurate case histories and study records; failure to provide the sponsor with sufficient financial information regarding a sub-investigator; failure to ensure the study was conducted in accordance with the general investigational plan and protocol; and failure to document reasons for early termination of subjects.  A letter responding to the Form FDA 483 was received from the investigator providing explanations and corrective actions. These findings will be evaluated upon receipt of the EIR.


 

 
 
Should you have any questions or comments about the contents of this memo or any aspect of Bioresearch Monitoring, please contact me at 301-827-6323. 
 
 
 
 
                                                        
                                                          Christine J. Drabick
                                                      Consumer Safety Officer